A hybrid 4-item Krousel-Wood Medication Adherence Scale predicts cardiovascular events in older hypertensive adults.
Aged
Antihypertensive Agents
/ therapeutic use
Cardiovascular Diseases
/ epidemiology
Cohort Studies
Female
Heart Failure
/ epidemiology
Humans
Hypertension
/ complications
Incidence
Male
Medication Adherence
Myocardial Infarction
/ epidemiology
Proportional Hazards Models
Self Report
Socioeconomic Factors
Stroke
/ epidemiology
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
22
4
2020
Statut:
ppublish
Résumé
There is a need for a brief, open access, self-report medication adherence scale that overcomes challenges of existing adherence tools, is associated with incident cardiovascular disease (CVD), and identifies low 'implementation' adherers to antihypertensive medications to facilitate blood pressure management. Antihypertensive medication adherence was assessed in a cohort of 1532 older hypertensive adults without prior CVD using the self-report 4-item Krousel-Wood Medication Adherence Scale (K-Wood-MAS-4), a hybrid tool developed to predict pharmacy refill and which captures four domains of adherence behavior: self-efficacy, physical function, intentional medication-taking, and forgetfulness. The 4-item scale categorized participants as low and high adherers using scores at least 1 and less than 1, respectively. Participants were followed after K-Wood-MAS-4 assessment to identify incident CVD events (stroke, myocardial infarction, congestive heart failure, or CVD death). The prevalence of low adherence was 38.7%. During a median follow-up of 2.8 years (maximum 3.8 years), 136 (8.9%) participants had an incident CVD event; 12.8 and 6.4% in low and high adherers, respectively. The adjusted hazard ratio (aHR) for incident CVD associated with low versus high adherence was 2.29 [95% confidence interval (CI): 1.61, 3.26]. Results were similar when stratified by age [<75 years - aHR 3.53 (95% CI: 1.65, 7.56); ≥75 years - aHR 1.98 (95% CI: 1.32, 2.97)], sex [women - aHR 1.90 (95% CI: 1.16, 3.12); men - aHR 2.80 (95% CI: 1.68, 4.65)], and race [black - aHR 2.22 (95% CI: 0.93, 5.31); white - aHR 2.26 (95% CI: 1.54, 3.34)]. Low medication adherence using the 'hybrid' K-Wood-MAS-4 predicts incident CVD in a cohort of older adults with established hypertension.
Sections du résumé
BACKGROUND
There is a need for a brief, open access, self-report medication adherence scale that overcomes challenges of existing adherence tools, is associated with incident cardiovascular disease (CVD), and identifies low 'implementation' adherers to antihypertensive medications to facilitate blood pressure management.
METHODS AND RESULTS
Antihypertensive medication adherence was assessed in a cohort of 1532 older hypertensive adults without prior CVD using the self-report 4-item Krousel-Wood Medication Adherence Scale (K-Wood-MAS-4), a hybrid tool developed to predict pharmacy refill and which captures four domains of adherence behavior: self-efficacy, physical function, intentional medication-taking, and forgetfulness. The 4-item scale categorized participants as low and high adherers using scores at least 1 and less than 1, respectively. Participants were followed after K-Wood-MAS-4 assessment to identify incident CVD events (stroke, myocardial infarction, congestive heart failure, or CVD death). The prevalence of low adherence was 38.7%. During a median follow-up of 2.8 years (maximum 3.8 years), 136 (8.9%) participants had an incident CVD event; 12.8 and 6.4% in low and high adherers, respectively. The adjusted hazard ratio (aHR) for incident CVD associated with low versus high adherence was 2.29 [95% confidence interval (CI): 1.61, 3.26]. Results were similar when stratified by age [<75 years - aHR 3.53 (95% CI: 1.65, 7.56); ≥75 years - aHR 1.98 (95% CI: 1.32, 2.97)], sex [women - aHR 1.90 (95% CI: 1.16, 3.12); men - aHR 2.80 (95% CI: 1.68, 4.65)], and race [black - aHR 2.22 (95% CI: 0.93, 5.31); white - aHR 2.26 (95% CI: 1.54, 3.34)].
CONCLUSION
Low medication adherence using the 'hybrid' K-Wood-MAS-4 predicts incident CVD in a cohort of older adults with established hypertension.
Identifiants
pubmed: 30817468
doi: 10.1097/HJH.0000000000001955
pii: 00004872-201904000-00026
pmc: PMC6485944
mid: NIHMS1520052
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-859Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR003096
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG022536
Pays : United States
Organisme : NICHD NIH HHS
ID : K12 HD043451
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108628
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM109036
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001417
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Prog Cardiovasc Nurs. 2000 Summer;15(3):90-6
pubmed: 10951950
Can J Cardiol. 2002 Jun;18(6):649-56
pubmed: 12107422
Am J Epidemiol. 2002 Nov 1;156(9):871-81
pubmed: 12397006
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
J Clin Epidemiol. 2003 Jun;56(6):520-9
pubmed: 12873646
Oncol Nurs Forum. 2003 Sep-Oct;30(5):811-21
pubmed: 12949594
Med Care. 2005 Jun;43(6):521-30
pubmed: 15908846
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Am J Manag Care. 2005 Jul;11(7):449-57
pubmed: 16044982
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Arch Intern Med. 2007 Sep 10;167(16):1798-803
pubmed: 17846400
J Card Fail. 2008 Apr;14(3):203-10
pubmed: 18381183
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Stroke. 2009 Jan;40(1):213-20
pubmed: 19038916
Am J Manag Care. 2009 Jan;15(1):59-66
pubmed: 19146365
Med Clin North Am. 2009 May;93(3):753-69
pubmed: 19427503
Am J Manag Care. 2009 Jul;15(7):457-64
pubmed: 19589013
Circulation. 2009 Oct 20;120(16):1598-605
pubmed: 19805653
J Gen Intern Med. 2010 Jun;25(6):495-503
pubmed: 20165989
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
J Hypertens. 2011 Mar;29(3):610-8
pubmed: 21157368
Clinicoecon Outcomes Res. 2011;3:47-54
pubmed: 21935332
Hypertension. 2011 Nov;58(5):804-10
pubmed: 21968751
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
Ann Intern Med. 2012 Oct 16;157(8):580-5
pubmed: 23070491
Clin Med Res. 2013 Jun;11(2):54-65
pubmed: 23580788
Pharmacotherapy. 2013 Aug;33(8):798-811
pubmed: 23649849
Prev Sci. 2015 Jan;16(1):21-30
pubmed: 24189743
Am J Med Sci. 2014 Aug;348(2):121-8
pubmed: 24978395
J Hypertens. 2015 Feb;33(2):412-20
pubmed: 25304468
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):347-56
pubmed: 26038524
Health Qual Life Outcomes. 2015 Sep 22;13:152
pubmed: 26396070
Med Clin North Am. 2017 Jan;101(1):229-245
pubmed: 27884232
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Eur J Prev Cardiol. 2018 Feb;25(3):287-297
pubmed: 29243510
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Behav Res Ther. 1997 Apr;35(4):373-80
pubmed: 9134792